The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combining low-dose regorafenib with pembrolizumab as a front-line therapy for patients with MSI-H colorectal cancer: REGPEM-CRC-01.
 
Ibrahim Halil Sahin
Consulting or Advisory Role - GlaxoSmithKline; Guardant Health; Seagen
Speakers' Bureau - Amgen; Pfizer
 
Ronan Hsieh
No Relationships to Disclose
 
Pashtoon Kasi
Leadership - Precision Biosensors
Stock and Other Ownership Interests - Elicio Therapeutics
Consulting or Advisory Role - Astellas Pharma; Bayer; BeiGene; BostonGene; BostonGene; Daiichi Sankyo/Astra Zeneca; Delcath Systems; Eisai; Elicio Therapeutics; Exact Sciences; Foundation Medicine; Guardant Health; Illumina; Ipsen (Inst); Lilly; MSD Oncology; Natera; NeoGenomics Laboratories; QED Therapeutics; Regeneron; SAGA Diagnostics; Seagen; SERVIER; Taiho Oncology; Taiho Pharmaceutical (Inst); Tempus; Xilio Therapeutics
Research Funding - Advanced Accelerator Applications (Inst); Boston Scientific (Inst); Tersera (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Vikram Gorantla
No Relationships to Disclose
 
Stacey Cohen
Consulting or Advisory Role - Abbvie; Agenus; Exact Sciences; Guardant Health; Incyte; Merck; Pfizer; Regeneron; Taiho Oncology
Research Funding - Biomea (Inst); BioNTech SE (Inst); Natera (Inst); Pfizer (Inst); Tempus (Inst)
Expert Testimony - The Cline Law Firm
Travel, Accommodations, Expenses - Biomea Fusion; Natera
 
John Rhee
No Relationships to Disclose
 
Rachael Safyan
Honoraria - Curio Science
Consulting or Advisory Role - Agenus; Guardant Health; Ipsen; Mirati Therapeutics
Research Funding - Exelixis (Inst); Replimune (Inst); Verastem (Inst)
 
Curtis Tatsuoka
No Relationships to Disclose
 
E. Gabriela Chiorean
No Relationships to Disclose
 
Patrick Boland
Consulting or Advisory Role - Abbvie; BeiGene; Bristol Myers Squibb Foundation; Taiho Oncology
Research Funding - Caris Life Sciences (Inst); Compass Therapeutics (Inst); MEI Pharma (Inst); Merck (Inst); Processa Pharmaceuticals (Inst)
 
Richard Kim
Honoraria - Natera
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Eisai; Exelixis; Jazz Pharmaceuticals; Pfizer; Roche/Genentech; SERVIER; Taiho Oncology
Speakers' Bureau - AstraZeneca; Incyte
 
Mohamedtaki Tejani
Consulting or Advisory Role - Exelixis
Speakers' Bureau - Natera
Research Funding - Bayer (Inst)
 
Anwaar Saeed
Consulting or Advisory Role - Arcus therapeutics; Astellas Pharma; AstraZeneca; Autem Therapeutics; Autem therapeutics; Bristol-Myers Squibb; Exelixis; Pfizer; Regeneron; Replimune; Taiho Pharmaceutical; Xilio therapeutics
Research Funding - Actuate Therapeutics (Inst); Arcus therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Incyte (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Oxford biotherapeutics (Inst); Phanes Therapeutics (Inst); Replimune (Inst)